ENA5 Antibody

What is CXCL5/ENA-78 antibody and what are its primary research applications?

CXCL5/ENA-78 antibody is an immunoglobulin that specifically recognizes and binds to the human chemokine CXCL5 (ENA-78). This chemokine plays significant roles in inflammatory processes, particularly in neutrophil recruitment and activation. The antibody is extensively used in research applications including:

• Neutralization assays to block CXCL5 activity in functional studies

• Western blotting for protein detection and quantification

• Chemotaxis inhibition studies

• Inflammatory pathway investigations

The commercially available antibodies, such as the polyclonal goat IgG format, are designed to detect human CXCL5/ENA-78 with high specificity in direct ELISAs and Western blots. These antibodies are developed using immunogens derived from E. coli-expressed recombinant human CXCL5/ENA-78 (Ala37-Asn114, Accession # P42830) .

How does the structure and specificity of CXCL5/ENA-78 antibodies affect their research utility?

The structure and specificity of CXCL5/ENA-78 antibodies are critical determinants of their research utility. Most commercially available CXCL5/ENA-78 antibodies are polyclonal antibodies, meaning they recognize multiple epitopes on the target protein. This characteristic provides several research advantages:

• Enhanced sensitivity for detecting native CXCL5/ENA-78 proteins

• Greater tolerance to minor changes in the target protein's conformation

• Robust signal generation in various detection methods

The specificity of these antibodies is typically validated through direct ELISAs and Western blotting assays. High-quality antibodies show minimal cross-reactivity with other chemokines, which is essential for accurately interpreting experimental results .

For neutralization studies, the antibody's ability to functionally block CXCL5/ENA-78 activity is quantified by the neutralization dose (ND50), which typically ranges from 4-16 μg/mL for high-quality antibodies when countering 30 ng/mL of recombinant human CXCL5/ENA-78 .

What quality control parameters should researchers verify when selecting CXCL5/ENA-78 antibodies?

When selecting CXCL5/ENA-78 antibodies for research, scientists should verify several critical quality control parameters:

Additionally, researchers should examine the antibody's performance in their specific application through validation studies. This is particularly important when transitioning between different experimental models or when adapting the antibody to new methodologies .

How can researchers optimize CXCL5/ENA-78 antibody use in chemotaxis inhibition assays?

Optimizing CXCL5/ENA-78 antibody use in chemotaxis inhibition assays requires careful consideration of several methodological factors:

• Antibody titration: Researchers should perform dose-response experiments to determine the optimal antibody concentration. Effective neutralization typically requires 4-16 μg/mL of antibody to counteract 30 ng/mL of recombinant human CXCL5/ENA-78, but this may vary depending on experimental conditions .

• Cell model selection: Validated cell models such as the BaF3 mouse pro-B cell line transfected with human CXCR2 provide reliable systems for measuring CXCL5-induced chemotaxis. The chemotactic response can be quantified using detection methods such as Resazurin-based assays (e.g., Catalog # AR002) .

• Appropriate controls: Experimental design should include:

  • Positive controls (cells exposed to CXCL5/ENA-78 without antibody)

  • Negative controls (cells without CXCL5/ENA-78 stimulation)

  • Isotype controls (non-specific antibody of the same isotype)

• Optimized incubation conditions: Pre-incubation of the antibody with CXCL5/ENA-78 before addition to cells may enhance neutralization efficiency.

Following these optimization steps will help ensure reproducible and reliable results in chemotaxis inhibition studies .

What are the best practices for using CXCL5/ENA-78 antibodies in Western blotting applications?

For optimal Western blotting results with CXCL5/ENA-78 antibodies, researchers should adhere to these best practices:

• Sample preparation:

  • For recombinant CXCL5/ENA-78: Use 50-100 ng per lane

  • For cell/tissue lysates: Optimize protein loading (typically 20-50 μg total protein)

  • Ensure complete denaturation with appropriate buffers containing reducing agents

• Antibody dilution optimization:

  • Typical starting dilutions: 0.2-1.0 μg/mL

  • Perform titration experiments to determine optimal concentration

  • Prepare antibody in blocking buffer (typically 5% non-fat dry milk or 3-5% BSA in TBST)

• Detection system selection:

  • For high sensitivity: HRP-conjugated secondary antibodies with enhanced chemiluminescence

  • For quantitative analysis: Fluorescently-labeled secondary antibodies with digital imaging

• Controls:

  • Positive control: Recombinant human CXCL5/ENA-78 protein

  • Negative control: Lysates from cells known not to express CXCL5/ENA-78

  • Technical control: Omission of primary antibody

• Verification of results:

  • CXCL5/ENA-78 should appear at approximately 8-9 kDa under reducing conditions

  • Higher molecular weight bands may indicate protein aggregation or post-translational modifications

These protocols should be optimized for each specific experimental setup and tissue/cell type being investigated .

How do different detection methods affect CXCL5/ENA-78 antibody performance?

Different detection methods significantly impact CXCL5/ENA-78 antibody performance, influencing sensitivity, specificity, and data interpretation:

When selecting a detection method, researchers should consider:

• Experimental question: Protein quantification versus localization versus functional inhibition

• Sample type: Purified protein, cell lysate, tissue section, or living cells

• Required sensitivity: Detection of endogenous versus overexpressed CXCL5/ENA-78

• Available equipment: Plate readers, flow cytometers, microscopes

Each method requires specific optimization steps for the antibody concentration, incubation times, washing protocols, and detection reagents. For example, neutralization assays typically require higher antibody concentrations (4-16 μg/mL) compared to Western blotting (0.2-1.0 μg/mL) .

How can researchers address specificity issues with CXCL5/ENA-78 antibodies?

When encountering specificity issues with CXCL5/ENA-78 antibodies, researchers should implement a systematic troubleshooting approach:

• Validate antibody performance:

  • Test against recombinant CXCL5/ENA-78 protein as a positive control

  • Examine cross-reactivity with other chemokines, particularly other CXC family members

  • Perform antibody validation using CXCL5/ENA-78 knockout or knockdown models if available

• Optimize experimental conditions:

  • Adjust antibody concentration to minimize non-specific binding

  • Modify blocking agents (consider switching between BSA, casein, or non-fat dry milk)

  • Increase washing stringency (duration, frequency, and detergent concentration)

  • Optimize antigen retrieval methods for tissue sections

• Implement additional controls:

  • Pre-absorption controls: Pre-incubate antibody with excess recombinant CXCL5/ENA-78

  • Secondary antibody-only controls to assess background

  • Isotype controls to distinguish specific from non-specific binding

• Consider alternative antibody formats:

  • If polyclonal antibodies show high background, consider monoclonal alternatives

  • Evaluate antibodies from different suppliers or different clones

  • Test antibodies raised against different epitopes of CXCL5/ENA-78

By systematically addressing these aspects, researchers can significantly improve specificity and reduce background issues in their experiments .

What essential controls should be included in CXCL5/ENA-78 antibody experiments?

Robust experimental design with appropriate controls is essential for valid and interpretable results when working with CXCL5/ENA-78 antibodies:

• Positive controls:

  • Recombinant human CXCL5/ENA-78 protein (e.g., E. coli-derived recombinant human CXCL5/ENA-78, Ala37-Asn114)

  • Cell lines or tissues known to express CXCL5/ENA-78 (e.g., stimulated epithelial cells)

  • For functional assays: BaF3 mouse pro-B cells transfected with human CXCR2

• Negative controls:

  • Cell lines or tissues known not to express CXCL5/ENA-78

  • Samples from CXCL5/ENA-78 knockout models where available

  • Buffer-only controls for background determination

• Antibody-specific controls:

  • Isotype control: Non-specific antibody of the same isotype and species origin

  • Concentration-matched control antibodies

  • Secondary antibody-only controls to assess non-specific binding

• Assay-specific controls:

  • For neutralization assays: Dose-response curves with increasing antibody concentrations

  • For Western blots: Molecular weight markers and loading controls

  • For ELISAs: Standard curves using recombinant protein

• Technical replicates:

  • Minimum of three replicates per experimental condition

  • Independent biological replicates to account for biological variation

Implementing these controls enables proper data interpretation and troubleshooting, ensuring experimental reliability and reproducibility .

How can researchers approach data contradictions in CXCL5/ENA-78 antibody-based findings?

When facing contradictory results in CXCL5/ENA-78 antibody-based experiments, researchers should employ a structured approach to resolve discrepancies:

• Methodological validation:

  • Verify antibody specificity through multiple detection methods

  • Confirm antibody lot consistency (lot-to-lot variations can significantly impact results)

  • Validate experimental protocols through independent replication

• Cross-platform verification:

  • Validate findings using multiple antibody-based techniques (e.g., ELISA, Western blot, immunocytochemistry)

  • Employ non-antibody-based methods for confirmation (e.g., mRNA expression, mass spectrometry)

  • Consider recombinant expression systems to verify functional findings

• Systematic analysis of variables:

  • Evaluate experimental variables that might contribute to discrepancies:

    • Sample preparation methods

    • Cell/tissue types and their activation states

    • Antibody concentration and incubation conditions

    • Detection systems and their sensitivity

• Biological context consideration:

  • Assess temporal dynamics of CXCL5/ENA-78 expression

  • Consider post-translational modifications that might affect antibody recognition

  • Evaluate potential splice variants or protein isoforms

• Collaborative validation:

  • Engage with other laboratories to independently replicate critical findings

  • Consider using computational antibody design approaches to develop antibodies with enhanced specificity and reduced batch-to-batch variation

By systematically addressing these factors, researchers can resolve contradictions and establish robust, reproducible findings .

How are computational approaches enhancing CXCL5/ENA-78 antibody design and functionality?

Computational approaches are revolutionizing antibody design and development, with implications for CXCL5/ENA-78 antibody research:

• Deep learning for antibody generation:

  • Recent advances in deep learning algorithms enable the computational generation of novel antibody sequences with desirable developability attributes

  • These approaches can generate thousands of potential antibody sequences that maintain high humanness (>90%) and medicine-like properties

  • In a recent study, 51 computationally designed antibodies were experimentally validated with excellent results for expression, stability, and low non-specific binding

• Structural modeling for epitope optimization:

  • Computational structural modeling allows prediction of antibody-antigen interactions

  • For CXCL5/ENA-78 antibodies, this enables design of variants targeting specific functional domains of the chemokine

  • These approaches can generate antibodies targeting regions critical for CXCL5-CXCR2 interactions

• Developability prediction algorithms:

  • Machine learning models can predict antibody properties including:

    • Expression levels

    • Thermal stability

    • Aggregation propensity

    • Non-specific binding

  • In validation studies, computationally designed antibodies exhibited high expression, high monomer content, and thermal stability comparable to clinically approved antibodies

• Benefits for research applications:

  • Reduced batch-to-batch variation compared to traditional polyclonal antibodies

  • More consistent performance across experimental conditions

  • Potential for developing antibodies against challenging epitopes

The application of these computational approaches to CXCL5/ENA-78 antibodies could significantly improve specificity, reduce background, and enhance reproducibility in research applications .

What role do CXCL5/ENA-78 antibodies play in studying inflammatory mechanisms?

CXCL5/ENA-78 antibodies serve as crucial tools for investigating inflammatory mechanisms across multiple disease models:

• Neutrophil recruitment studies:

  • CXCL5/ENA-78 is a potent neutrophil chemoattractant acting through CXCR2

  • Neutralizing antibodies allow researchers to specifically block this pathway

  • Chemotaxis inhibition can be quantified using specialized assays, where CXCL5/ENA-78 has been shown to chemo-attract CXCR2-expressing cells in a dose-dependent manner

• Inflammatory disease models:

  • CXCL5/ENA-78 is implicated in various inflammatory conditions including:

    • Acute lung injury

    • Rheumatoid arthritis

    • Inflammatory bowel disease

    • Atherosclerosis

  • Antibodies enable precise manipulation of the CXCL5/ENA-78 pathway in these models

• Signaling pathway analysis:

  • Neutralizing antibodies help delineate the specific contribution of CXCL5/ENA-78 in complex inflammatory cascades

  • This approach allows researchers to distinguish CXCL5/ENA-78 effects from those of other CXC chemokines that activate CXCR2

• Biomarker validation:

  • Anti-CXCL5/ENA-78 antibodies are essential for developing quantitative assays to measure CXCL5/ENA-78 levels in biological samples

  • These measurements can validate CXCL5/ENA-78 as a biomarker for inflammatory conditions

• Therapeutic target validation:

  • Neutralization studies using CXCL5/ENA-78 antibodies help establish proof-of-concept for therapeutic targeting of this chemokine

  • The typical neutralization dose (ND50) of 4-16 μg/mL provides a baseline for therapeutic antibody development

By enabling these research applications, CXCL5/ENA-78 antibodies contribute significantly to our understanding of inflammatory processes and potential therapeutic interventions .

How can researchers validate CXCL5/ENA-78 antibodies for use across different species?

Cross-species validation of CXCL5/ENA-78 antibodies requires a systematic approach to ensure reliable results when transitioning between model organisms:

• Sequence homology analysis:

  • CXCL5/ENA-78 shows variable conservation across species

  • Researchers should perform sequence alignments to identify regions of high homology

  • Antibodies targeting highly conserved epitopes have greater potential for cross-species reactivity

• Step-wise experimental validation:

  • Begin with in silico prediction of cross-reactivity based on epitope conservation

  • Perform Western blots with recombinant CXCL5/ENA-78 from target species

  • Validate in cell/tissue lysates from the target species

  • Confirm functional neutralization in species-specific bioassays

• Controls for cross-species validation:

  • Positive controls: Samples from species known to be reactive

  • Negative controls: Samples from CXCL5/ENA-78 knockout models if available

  • Competition assays: Pre-absorption with species-specific recombinant proteins

• Optimization strategies for cross-species applications:

  • Adjust antibody concentration for different species (may require higher concentrations)

  • Modify incubation conditions (temperature, time, buffer composition)

  • Consider using secondary detection systems optimized for the target species

• Documentation of cross-reactivity:

  • Systematically document observed cross-reactivity for each application

  • Create a validation matrix specifying species, applications, and required conditions

  • Share validation data with the research community to enhance reproducibility

When commercial antibodies like the Human CXCL5/ENA-78 Antibody (listed in search results) specify "Human" as the species reactivity, researchers should not assume cross-reactivity with other species without proper validation .

How are CXCL5/ENA-78 antibodies being integrated into multiplexed detection systems?

CXCL5/ENA-78 antibodies are increasingly being incorporated into sophisticated multiplexed detection platforms that enable simultaneous analysis of multiple inflammatory mediators:

• Multiplex bead-based immunoassays:

  • Allow concurrent quantification of CXCL5/ENA-78 alongside other chemokines and cytokines

  • Enable comprehensive profiling of inflammatory signatures with minimal sample volume

  • Require careful validation to ensure antibody performance is maintained in multiplex format

  • Cross-reactivity testing becomes even more critical in multiplexed systems

• Antibody arrays and protein chips:

  • Spatially organized antibodies including anti-CXCL5/ENA-78 on solid surfaces

  • Enable high-throughput screening of multiple samples

  • Require optimization of antibody density and spacing to prevent steric hindrance

  • Surface chemistry modifications may be necessary to maintain antibody functionality

• Single-cell analysis platforms:

  • Integration with mass cytometry (CyTOF) or spectral flow cytometry

  • Allow correlation of CXCL5/ENA-78 production with cellular phenotypes

  • Require conjugation of CXCL5/ENA-78 antibodies with metal isotopes or fluorophores

  • Validation of antibody performance post-conjugation is essential

• Digital spatial profiling:

  • Combining CXCL5/ENA-78 antibodies with spatial transcriptomics

  • Maps CXCL5/ENA-78 protein expression in tissue context

  • Requires optimization of antibody penetration in tissue sections

  • May involve specialized fixation protocols to preserve epitope recognition

These integrated approaches provide richer datasets but require rigorous validation to ensure CXCL5/ENA-78 antibody specificity is maintained within complex detection systems .

What are the latest advances in CXCL5/ENA-78 antibody engineering for therapeutic applications?

Recent advances in antibody engineering are expanding the potential therapeutic applications of CXCL5/ENA-78 antibodies:

• Computationally designed antibodies:

  • Deep learning algorithms now enable generation of antibody sequences with optimal developability characteristics

  • A recent study demonstrated that computationally generated antibodies exhibit high expression, monomer content, and thermal stability

  • These approaches can potentially create CXCL5/ENA-78 antibodies with enhanced specificity and reduced immunogenicity

• Bispecific antibody formats:

  • Novel formats targeting both CXCL5/ENA-78 and its receptor CXCR2

  • Enhanced neutralizing capacity through simultaneous targeting of ligand and receptor

  • Potential for improved efficacy in inflammatory disease models

  • Requires specialized validation protocols to confirm dual binding capacity

• Antibody fragments and alternative scaffolds:

  • Single-chain variable fragments (scFvs) and nanobodies against CXCL5/ENA-78

  • Improved tissue penetration and reduced immunogenicity

  • Enhanced production efficiency in bacterial expression systems

  • May require different optimization strategies than full-length antibodies

• Antibody-drug conjugates (ADCs):

  • Conjugation of CXCL5/ENA-78 antibodies with anti-inflammatory payloads

  • Targeted delivery to sites of high CXCL5/ENA-78 expression

  • Reduction of systemic side effects through localized drug delivery

  • Requires careful optimization of drug-antibody ratio and linker chemistry

These engineering approaches represent the cutting edge of CXCL5/ENA-78 antibody development, with potential applications in both research and therapeutic settings .

How does antibody validation differ between research and clinical diagnostic applications for CXCL5/ENA-78?

The validation requirements for CXCL5/ENA-78 antibodies differ significantly between research and clinical diagnostic applications:

For clinical diagnostic applications, additional validation steps include:

• Analytical validation:

  • Precision studies (intra-assay, inter-assay, inter-lot)

  • Linearity across the measuring range

  • Recovery in various matrices

  • Interference testing with common substances (lipids, hemoglobin, etc.)

• Clinical validation:

  • Establishment of reference ranges in healthy populations

  • Correlation with existing diagnostic methods

  • Assessment of clinical sensitivity and specificity

  • Determination of positive and negative predictive values

• Quality control requirements:

  • Implementation of internal quality control procedures

  • Participation in external quality assessment programs

  • Stability testing under various storage conditions

  • Shelf-life determination with real-time and accelerated studies

While research applications focus on experimental utility, clinical diagnostic applications must meet stringent regulatory requirements for patient testing. Researchers transitioning CXCL5/ENA-78 antibodies to clinical applications must be prepared for this substantial increase in validation requirements .

How can dynamic range limitations be addressed when quantifying CXCL5/ENA-78 across diverse sample types?

Addressing dynamic range limitations for CXCL5/ENA-78 quantification requires tailored methodological approaches for different sample types:

• Modified immunoassay strategies:

  • Development of high-sensitivity ELISAs with signal amplification systems

  • Implementation of sample dilution protocols with automated validation

  • Use of kinetic measurement approaches rather than endpoint detection

  • Extension of standard curves to capture wider concentration ranges

• Sample type-specific optimizations:

  • Serum/plasma: Pre-treatment protocols to remove interferents

  • Cell culture supernatants: Concentration adjustments based on cell density

  • Tissue homogenates: Standardization of extraction methods

  • Bronchoalveolar lavage fluid: Concentration steps for low-abundance samples

• Digital detection technologies:

  • Single molecule array (Simoa) technologies for ultra-low concentration detection

  • Droplet digital ELISA for absolute quantification without standard curves

  • Implementation of multiple detector gain settings for extended dynamic range

• Analytical strategies for complex samples:

  • Multiple dilution approach with overlapping ranges

  • Internal calibration with spike-in controls

  • Standard addition methods for matrix effect compensation

  • Mathematical modeling to extend quantification beyond standard curves

These refined methodologies enable accurate CXCL5/ENA-78 quantification across the wide concentration ranges typically encountered in different experimental and clinical contexts .

What considerations should guide selection between polyclonal and monoclonal CXCL5/ENA-78 antibodies?

Selecting between polyclonal and monoclonal CXCL5/ENA-78 antibodies requires careful consideration of experimental objectives and technical requirements:

Decision framework for selection:

• Choose polyclonal antibodies when:

  • Detecting native proteins with unknown conformation

  • Maximum sensitivity is required

  • The protein target may exist in multiple forms

  • Preliminary studies are being conducted

• Choose monoclonal antibodies when:

  • Absolute specificity is critical

  • Long-term reproducibility is essential

  • Specific epitopes need targeting

  • Large-scale or clinical studies are planned

• Consider computational design approaches:

  • For novel antibodies with optimized characteristics

  • When traditional methods yield suboptimal results

  • To reduce immunogenicity in potential therapeutic applications

  • To enhance developability attributes like stability and expression

The polyclonal goat anti-human CXCL5/ENA-78 antibody described in the search results offers good versatility for research applications, while computationally designed antibodies represent an emerging alternative with potential advantages in consistency and performance .

How can researchers implement longitudinal stability testing for CXCL5/ENA-78 antibodies?

Implementing a robust longitudinal stability testing program for CXCL5/ENA-78 antibodies ensures consistent performance over time and across experimental series:

• Establish a reference standard system:

  • Create master antibody aliquots stored under optimal conditions (-80°C)

  • Prepare working standards with defined activity units

  • Implement a qualification system for new antibody lots against reference standards

• Design comprehensive stability protocols:

  • Real-time stability testing under recommended storage conditions

  • Accelerated stability studies at elevated temperatures

  • Freeze-thaw cycle testing (typically 5-10 cycles)

  • Stress testing under extreme conditions (pH, temperature, oxidation)

• Define critical quality attributes for monitoring:

  • Binding activity (ELISA against recombinant CXCL5/ENA-78)

  • Functional activity (neutralization potency in cell-based assays)

  • Physical stability (SEC-HPLC for aggregation assessment)

  • Chemical stability (LC-MS for degradation products)

• Implement a systematic testing schedule:

  • Initial characterization (T0)

  • Short-term stability points (1, 3, 6 months)

  • Long-term stability points (12, 24, 36 months)

  • After any significant environmental exposure or handling event

• Data management and trend analysis:

  • Document all stability data in a centralized system

  • Implement statistical process control methods

  • Establish alert and action limits for parameter shifts

  • Analyze trending to predict stability issues before failure

This systematic approach allows researchers to confidently use CXCL5/ENA-78 antibodies in longitudinal studies while ensuring data comparability across time points. It also contributes to improved reproducibility in CXCL5/ENA-78 research by establishing rigorous quality control standards .